Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for:
For this indication, competent medicine agencies globally authorize below treatments:
85 - 85 mg per m² of body surface area (BSA)
From 85 To 85 mg per m² of body surface area (BSA) once every 14 day(s)
The recommended dose for oxaliplatin in adjuvant setting is 85 mg/m² intravenously repeated every two weeks for 12 cycles (6 months).
The recommended dose for oxaliplatin in treatment of metastatic colorectal cancer is 85 mg/m² intravenously repeated every 2 weeks.
Dosage given should be adjusted according to tolerability.
Oxaliplatin should always be administered before fluoropyrimidines-i.e. 5-fluorouracil (5 FU).
Oxaliplatin is administered as a 2- to 6-hour intravenous infusion in 250 to 500 ml of 5% glucose solution (50mg/ml) to give a concentration between 0.2 mg/ml and 0.70 mg/ml; 0.7 mg/ml is the highest concentration in clinical practice for an oxaliplatin dose of 85 mg/m².
Oxaliplatin was mainly used in combination with continuous infusion 5-fluorouracil based regimens. For the two-weekly treatment schedule 5-fluorouracil regimens combining bolus and continuous infusion were used.
Oxaliplatin diluted in 250 to 500 ml of 5% glucose solution to give a concentration not less than 0.2 mg/ml must be infused via a central venous line or peripheral vein over 2 to 6 hours. Oxaliplatin infusion should always precede that of 5-fluorouracil.